These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22517848)

  • 21. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The molecular pathogenesis and prognosis of renal cell carcinoma].
    Serth J
    Urologe A; 2007 Sep; 46(9):1168-9. PubMed ID: 17668170
    [No Abstract]   [Full Text] [Related]  

  • 23. Mixed epithelial and stromal tumor of the kidney.
    Nandeesh BN; Rajalakshmi T; Mehta H
    Indian J Cancer; 2010; 47(3):345-6. PubMed ID: 20587916
    [No Abstract]   [Full Text] [Related]  

  • 24. [Progression of late metastases of renal cell carcinoma].
    Wittekind C
    Dtsch Med Wochenschr; 2006 Apr; 131(17):994. PubMed ID: 16673224
    [No Abstract]   [Full Text] [Related]  

  • 25. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
    Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
    [No Abstract]   [Full Text] [Related]  

  • 26. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
    Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
    EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
    Hahn AW; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100190. PubMed ID: 32679555
    [No Abstract]   [Full Text] [Related]  

  • 28. [Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy].
    Störkel S
    Pathologe; 2010 Feb; 31(1):50-3. PubMed ID: 20084384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA‑373 promotes tumorigenesis of renal cell carcinoma in vitro and in vivo.
    Li Y; Zhang D; Wang J
    Mol Med Rep; 2017 Nov; 16(5):7048-7055. PubMed ID: 28901426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular tumor board-renal cell carcinoma].
    Grünwald V; Doehn C; Goebell PJ
    Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular genetic changes in renal cell carcinomas].
    Buentig N; Störkel S; Atzpodien J
    Urologe A; 2002 Sep; 41(5):475-81. PubMed ID: 12426866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
    Stühler V; Bedke J
    BMC Med; 2016 Dec; 14(1):201. PubMed ID: 27923360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
    Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
    Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissecting tumour heterogeneity in flies: genetic basis of interclonal oncogenic cooperation.
    Ohsawa S; Takemoto D; Igaki T
    J Biochem; 2014 Sep; 156(3):129-36. PubMed ID: 25012819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney cancer: treatment of clinically localized renal tumors in the elderly.
    Roos FC; Thüroff JW
    Nat Rev Urol; 2011 Oct; 8(11):595-6. PubMed ID: 21989303
    [No Abstract]   [Full Text] [Related]  

  • 39. Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology.
    Sanfrancesco JM; Cheng L
    Crit Rev Oncol Hematol; 2017 Nov; 119():23-28. PubMed ID: 29065981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel agents and approaches for advanced renal cell carcinoma.
    Wang L; Lee BR
    J Urol; 2012 Sep; 188(3):716. PubMed ID: 22818344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.